title: Sweet syndrome as terminal event in ruxolitinib-treated myelofibrosis.
authors.affiliation: Department of Haematology, Barking, Havering and Redbridge University Hospitals NHS Trust, London, UK. basabi.chatterjee2@bartshealth.nhs.uk.
authors.forename: Basabi
authors.initials: B
authors.lastname: Chatterjee
authors.forename: Usama
authors.initials: U
authors.lastname: Rqieh
authors.forename: Paul
authors.initials: P
authors.lastname: Greaves
authors.forename: Daniela
authors.initials: D
authors.lastname: Piras
authors.forename: John
authors.initials: J
authors.lastname: Firth
authors.forename: Khalid
authors.initials: K
authors.lastname: Saja
mesh_terms: D000368:Aged; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000150:complications* / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines; D012867:Skin / Q000473:pathology; D016463:Sweet Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*
chemical_list: D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib